Las Condes

126 / 164

256
100.Turner L W, Nartey D, Stafford R S, Singh S, Alexander G C.
Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–
2012. Diabetes Care 2014; 37:985–992.
101.Gerich JE. Role of the kidney in normal glucose homeostasis
and in the hyperglycaemia of diabetes mellitus: therapeutic
implications. Diabet Med. 2010; 27:136-142.
102.DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys
in glucose homeostasis: a new path towards normalizing
glycaemia. Diabetes Obes Metab. 2012; 14:5–14.
103.Wright EM, Loo DD, Hirayama BA. Biology of human sodium
glucose transporters. Physiol Rev 2011; 91:733–794.
104.Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-
glucose transport: role in diabetes mellitus and potential
clinical implications. Kidney International 2009; 75: 1272–
1277.
105.Bays H. Sodium Glucose Co-transporter Type 2 (SGLT2)
Inhibitors: Targeting the Kidney to Improve Glycemic Control
in Diabetes Mellitus Diabetes Ther 2013; 4:195–220.
106.Fujita Y and Inagaki N. Renal sodium glucose cotransporter
2 inhibitors as a novel therapeutic approach to treatment
of type 2 diabetes: Clinical data and mechanism of action. J
Diabetes Invest 2014; 5: 265–275.
107.Wright EM, Hirayama BA, Loo DF. Active sugar transport in
health and disease. J Int Med. 2007; 261:32-43.
108.Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review.
Diabetes Metab Res Rev. 2005; 21:31-38.
109.Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal
Na+-glucose cotransporters, may provide a novel approach to
treating diabetes. Diabetes. 1999; 48:1794–1800.
110.Chao EC, Henry RR. SGLT2 inhibition - a novel strategy for
diabetes treatment. Nat Rev Drug Discov 2010; 9: 551–559.
111. Handelsman Y. Potential Place of SGLT2 Inhibitors in Treatment
Paradigms for Type 2 Diabetes Mellitus. Endocr Pract. 2015;
21(9):1054-1065.
112.Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response
to sodium-glucose cotransporter 2 inhibition in type 2 diabetic
patients. J Clin Invest 2014; 124: 499–508.
113.Berhan A and Barker A. Sodium glucose co-transport 2
inhibitors in the treatment of type 2 diabetes mellitus: a
meta-analysis of randomized double-blind controlled trials
BMC Endocrine Disorders 2013; 13:58-69.
114.Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos
A, Bekiari E et al. Sodium-glucose cotransporter 2 inhibitors
for type 2 diabetes: A systematic review meta-analysis. Ann
Intern Med. 2013; 159(4):262–274.
115.Mikhail N. Place of sodium-glucose co-transporter type 2
inhibitors for treatment of type 2 diabetes. World J Diabetes
2014; 5(6): 854-859.
116.Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin
KW, White WB. Effects of sodium-glucose co-transporter 2
inhibitors on blood pressure: a systematic review and meta-
analysis. J Am Soc Hypertens 2014; 8: 262-275.
117.Valentine V and Hinnen D. Clinical Implications of Canagliflozin
Treatment in Patients with Type 2 Diabetes. Clinical Diabetes
2015; 33: 5-13.
118.Sinclair A, Bode B, Harris S, Vijapurkar U, Mayer C, Fung A et al.
Efficacy and safety of canagliflozin compared with placebo in
older patients with type 2 diabetes mellitus: a pooled analysis
of clinical studies. BMC Endocr Disord 2014; 14: 37-48.
119.Nauck MA. Update on developments with SGLT2 inhibitors in
the management of type 2 diabetes Drug Design, Development
and Therapy 2014:8 1335–1380.
120.Monami M, Nardini C, Mannucci E. Efficacy and safety of
sodium glucose co-transport-2 inhibitors in type 2 diabetes:
a meta-analysis of randomized clinical trials. Diabetes Obes
Metab 2014;16:457–466.
121.Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel
S et al. SGLT-2 inhibitors and cardiovascular risk: Proposed
pathways and review of ongoing outcome trials. Diab Vasc Dis
Res. 2015; 12:90-100.
122.Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel
S, et al. EMPA-REG OUTCOME Investigators. Empagliflozin,
Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N
Engl J Med. 2015; 373:2117-2128.
123.Garber AJ, Abrahamson MJ, Barzilay JI, MD, Blonde L,
Bloomgarden ZT, Bush MA et al. Consensus statement by
the American Association of Clinical Endocrinologists and
American College of Endocrinology on the comprehensive
type 2 diabetes Management algorithm – 2016 executive
summary. Endocrine Practice 2016; 22: 84-113.
124.Kohan DE, Fioretto P, Tang W, List JF. Longterm study of
patients with type 2 diabetes and moderate renal impairment
shows that dapagliflozin reduces weight and blood pressure
but does not improve glycemic control. Kidney Int 2014; 85:
962–971.
125.FDA Drug Safety Communication: FDA revises label of diabetes
drug canagliflozin to include updates on bone fracture risk and
new information on decreased bone mineral density.
126.Ljunggren Ö, Bolinder J, Johansson L, Wilding J, Langkilde
AM et al. Dapagliflozin has no effect on markers of bone
formation and resorption or bone mineral density in patients
with inadequately controlled type 2 diabetes mellitus on
metformin. Diabetes Obes Metab 2012; 14:990–999.
127.FDA Drug Safety Communication: FDA warns that SGLT2
inhibitors for diabetes may result in a serious condition of too
much acid in the blood
ucm446845.htm
128.AACE/ACE Scientific and Clinical Review: Association of SGLT2
Inhibitors and DKA. Conclusion Summary, October 2015.
Conclusions.pdf.
[REV. MED. CLIN. CONDES - 2016; 27(2) 235-256]